由电解质失衡和物质使用引发的诱发性发作:一个案例报告
1National University of Natural Medicine, Portland, OR.
Integrative medicine (Encinitas, Calif.)
|November 13, 2024
概括
第一次发作需要仔细评估,以区分被挑起和未被挑起的发作. 这个案例凸显了旅行者的腹,酒精和THC使用如何引起发作,强调了详细的病史和电解质评估.
科学领域:
- 神经学 神经学
- 紧急医疗 紧急医疗
- 临床诊断 临床诊断 临床诊断
背景情况:
- 第一次发作带来了诊断上的挑战,需要区分被挑起的和未被挑起的病因.
- 识别诱发因素对于准确诊断和治疗发作至关重要.
研究的目的:
- 探讨评估第一次发作的诊断挑战.
- 强调区分被挑和未被挑的发作的重要性.
- 突出多因素影响在发作挑中的作用.
主要方法:
- 一个65岁的女性第一次发作的案例报告.
- 包括实验室评估在内的全面评估.
- 对重叠因素的分析:旅行者的腹,酒精消费和THC使用.
主要成果:
- 患者的发作被归类为被挑起的.
- 实验室发现包括高血红素和边缘缺乏症.
- 诊断过程没有受到报告限制或延迟医疗转移的阻碍.
结论:
- 详细的病史对于评估疑似首次发作至关重要.
- 有针对性的电解质评估和水化策略对于临床决策至关重要.
- 识别多因素的影响有助于将发作分类为被挑起的.
相关概念视频
Seizures: Classification
303
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
303
Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147
Arteries of the Lower Limbs
178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
253
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
253
Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
Antiepileptic Drugs: GABAergic Pathway Potentiators
334
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
334


